Publications

44 peer-reviewed publications, primarily in oncology: 24 are in journals with an impact factor > 5. My current h-index is 23.
L.C Gilligan, J. Bradbury, A.E Taylor, S. He, D.M O’Neil, M. Viant, P.A Foster. A novel UPLC-MS/MS method to extract and quantify sulphated and non-sulphated oestrogens automatically optimised using MUSCLE software. J Chromatography. In preparation.
L.C. Gilligan, A-M. Hewitt, A. Kupryte, K. Burnell, D. Morton, P.A. Foster. Oestrogen metabolism is dysregulated by TNF-alpha and IL-6 in colorectal adenoma and carcinoma. Carcinogenesis. In preparation.
G. P. Prevost, S Xu, M. Garrido, M. Serova, O.D.E. Vewer, C. Gespach, J-F. Briand, A. Tijeras-Raballand, M. Gutmann, A. Hendrix, M. Sabbah, A. Chachereau, A. de Gramont, N. Neamati, M-H. Pitty, P.A. Foster. XCE853: a novel PDI inhibitor that inhibits proliferation of human tumor cells ex vivo, in vitro and in vivo. Cancer Res. In Preparation
Submitted/In Preparation
Published
44. P.A. Foster, J.W. Mueller. Insights into steroid sulfation and desulfation pathways. J Mol Endocrinol. 2018;[ePub ahead of print].
43. V. Chortis, A.E. Taylor, C.L. Doig, M.D. Walsh, E. Meimaridou, C. Jenkinson, G. Rodriguez-Blanco, C.L. Ronchi, A. Jafri, L.A. Metherell, D. Hebenstreit, W.B. Dunn, W. Arlt, P.A. Foster. Nicotinamide Nucleotide Transhydrogenase as a novel treatment target in adrenocortical carcinoma. Endocrinol. 2018;[ePub ahead of print]
42. D.A. Gibson, P.A. Foster, I. Simitsidellis, H. Critchley, O. Kelepouri, F. Collins, P.T. Saunders. A role for steroid sulfatase in intracrine regulation of endometrial decidualisation. J Mol Endocrinol. 2018;[ePub ahead of print]
41. W. Dohle, F.L. Jordan, G. Menchon, A.E. Prota, P.A. Foster, P. Mannion, E. Hamel, M.P.Thomas, P.G. Kasprzyk, E. Ferrandis, M.O. Steinmetz, M.P. Leese, B.V.L. Potter. Quinazolinone-based anticancer agents: Synthesisantiproliferative SAR, antitubulin activity, and tubulin co-crystal structure. J Med Chem. 2018;61:1031-1044.
40. E. Meimaridou, M. Goldsworthy, V. Chortis, E. Fragouli, P.A. Foster, W. Arlt, R. Cox, L.A. Metherell. NNT is a key regulator of adreanl redox homeostasis and steroidogenesis in male mice. J Endocrinol. 2018;236:13-28.
39. L.C. Gilligan, H.P. Rahman, A.M. Hewiit, A.J. Sitch, A. Gondal, A. Arvaniti, A.E. Taylor, M.L. Read, D.G. Morton, P.A. Foster. Estrogen activation by steroid sulfatase increases colorectal cancer proliferation via GPER. J Clin Endocrinol Metab. 2017;102:4435-4447.
38. L.C. Gilligan, A. Gondal, V. Tang, M.T. Hussain, A. Arvaniti, A.M. Hewitt, P.A. Foster. Estrone sulfate transport and steroid sulfatase activity in colorectal cancer: Implications for hormone replacement therapy. Front Pharmacol. 2017;8:103.
37. H.P. Rahman, J. Hofland, P.A. Foster. In touch with your feminine side: how oestrogen metabolism impacts prostate cancer. Endocr Relat Cancer. 2016;23:R249-66.
36. M.I. El-Gamal, M.H. Semreen, P.A. Foster, B.V.L. Potter. Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors. Bioorg Med Chem. 2016;24:2762-7.
32. F. Meyer-Losic, S.P. Newman, J.M. Day, M.J. Reed, P.G. Kasprzyk, A. Purohit, P.A. Foster. STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t antigen transgenic mice. PLoS One. 2013;8:e80305.
20. P.A. Foster, M.J.Reed, A. Purohit. Recent developments of steroid sulfatase inhibitors as anti-cancer agents. Anti-cancer Agents in Med. Chem. Review. 2008; 8: 732-8.
19. P.A. Foster, S.K. Chander, M.F.C. Parsons, S.P. Newman, L.W.L.Woo, B.V.L.Potter, M.J. Reed, A. Purohit. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res. Treat. 2008; 111:129-38.
18. P.A. Foster, Y.T. Ho, S.P. Newman, P.G. Kasprzyk, M.P. Leese, B.V.L.Potter, M.J. Reed, A. Purohit. 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res. Treat. 2008; 111:251-60.
17. P.A. Foster, L.W. Woo, B.V. Potter, M.J. Reed, A. Purohit. Steroid sulfatase inhibitors block the growth of hormone-dependent endometrial cancer xenografts: A potential new treatment. Endocinology. 2008; 149:4035-42.
16. P.A. Foster. Steroid metabolism in breast cancer. Minerva Endocrinologica. 2008;33:27-37.
15. P.A. Foster, S.P. Newman, M.P. Leese, S. Bernetiere, J. Camara, B.V. Potter, M.J. Reed, A. Purohit. A new micronised formulation of 2-methoxyestradiol-bis-sulphamate is therapeutically potent against breast cancer. Anti-cancer Res. 2008; 28:577-81.
14. P.A.Foster, C. Stengal, T. Ali, M.P.Leese, B.V.L. Potter, M.J. Reed, A. Purohit, S.P. Newman. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anti-cancer Res. 2008; 28:1483-91.
13. J.M. Day, P.A. Foster, H.J. Tutill, M.F.C. Parsons, S.K. Chander, G.M. Allan, H.R. Lawrence, N. Vicker, B.V.L. Potter, M.J. Reed, A. Purohit. In vivo inhibition of estrone-stimulated tumor growth by STX1040; a 17b-hydroxysteroid dehydrogenase type 1 inhibitor with therapeutic potential. Int. J. Can. 2008;122:1931-1940.
12. S.P. Newman, P.A. Foster, C. Stengel, J.M. Day, Y.T. Ho, M.P. Leese, B.V.L. Potter, M.J. Reed, A. Purohit. The orally bioavailable microtubule disruptor, STX140, is efficacious in vitro and in vivo in Taxane resistant breast carcinoma cells. Clin. Can. Res. 2008; 14:597-606.
11. M.P. Leese, F.L. Jourdan, K. Gaukroger, M.F. Mahon, S.P. Newman, P.A. Foster, C. Stengal, S. Regis-Lydi, E Ferrandis, A.D. Fiore, G. De Simone, C.T. Supuran, A. Purohit, M.J. Reed, P.V.L. Potter. Structure-activity relationships of C-17 Cyano-substituted estratrienes as anticancer agents. J. Med. Chem. 2008; 51:1295-308.
10. L.W. Woo, D.S. Fischer, C.M. Sharland, M. Trusselle, P.A. Foster, S.K. Chander, A. Di Fiore, C.T. Supuran, G. De Simone, A. Purohit, M.J. Reed, B.V. Potter. Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modelling, and protein crystallography. Mol. Cancer Ther. 2008; 7: 2435-44.
9. S.P. Newman, P.A. Foster, Y.T. Ho, J.M. Day, B. Raobaikady, P.G. Kasprzyk, M.P. Leese, B.V. Potter, M.J. Reed, A. Purohit. The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptos as therapy for hormone-independent prostate and breast cancer. Br. J. Cancer. 2007; 97, 1673-82.
8. S.K. Chander, P.A. Foster, M.P. Leese, S.P. Newman, B.V.L. Potter, M.J. Reed, A. Purohit. In vivo inhibition of angiogenesis by sulfamoylated derivatives of 2-methoxyestradiol. Br. J. Cancer. 2007; 96, 1368-76.
7. P.A. Foster, S.P. Newman, S.K. Chander, C. Stengal, R. Jhalli, L.W.L. Woo, B.V.L. Potter, M.J. Reed, A. Purohit. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin. Can. Res. 2006; 12, 5543-49.
6. R.S. Scotland, Cohen M, P.A. Foster, M. Lovell, A. Mathur, A. Ahluwalia, A.J. Hobbs. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. PNAS. 2005; 102, 14452-7.
5. A. Ahluwalia, P. Foster, R.A. Scotland, M.G. McLean, A. Mathur, M. Perretti, S. Moncada, A.J. Hobbs. Anti-inflammatory activity of soluble guanalyte cyclase: cyclic GMP-dependent down regulation of P-selectin expression and leukocyte recruitment. PNAS. 2004; 101, 1386-1391.
4. A. Hobbs, P.A. Foster, C. Prescott, R. Scotland, A. Ahluwalia. Natriuretic peptide receptor-C regulates blood flow and prevents myocardial ischemia/reperfusion injury: a novel cardioprotective role for endothelium-derived C-type natiuretic peptide. Circulation 2004; 101, 1231-5.
3. P.A. Foster, S.K.P. Costa, R. Postin, J.R.S. Hoult and S.D. Brain. Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor. FASEB. 2003; 17, 1703-5.
2. P.A. Foster, S. Wicks, M. Foster and S.D. Brain. Cellular pathology changes in rat skin following intradermal injection of nerve growth factor (NGF): neutrophil dependent and independent events. J. Pathol. 2002; 197, 245-255.
1. D.Q. Chu, M. Choy, P.A. Foster, T. Cao and S.D. Brain. A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin13-52 to modulate microvascular but not thermal hyperalgesia response. Br. J. Pharmacol. 2000; 130, 1589-1596.
Patents
- Foster, P.A. Newman, S.P. Woo, L.W.L. Reed, M.J. Purohit, A. Potter, B.V.L. Treatment of oestrogen dependent condition using dual aromatase-sulphatase inhibitors (DASI). Patent pending.
- Foster, P.A. Tagg, S.L. Newman, S.P. Reed, M.J. Purohit, A. Potter, B.V.L. Composition comprising a glycolytic inhibitor and an A-ring system comprising a sulphamate group for the treatment of cancer. U.S. Patent 20100144652. June 10, 2010.
- Potter, B.V.L. Reed, M.J. Woo, L.W.L. Purohit, A. Foster, P.A. Steroidal compounds as steroid sulphatase inhibitors. U.S. Patent 20090182000. July 16, 2009.
